Affimed N.V. – NASDAQ:AFMD
Affimed N.V. stock price today
$0.182
-1.10
-85.93%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 3 days
Affimed N.V. stock price monthly change
-74.95%
month
Affimed N.V. stock price quarterly change
-74.95%
quarter
Affimed N.V. stock price yearly change
+173.19%
year
Affimed N.V. key metrics
Market Cap | 17.79M |
Enterprise value | N/A |
P/E | -1.09 |
EV/Sales | -2.41 |
EV/EBITDA | 1.34 |
Price/Sales | 2.22 |
Price/Book | 0.49 |
PEG ratio | -0.27 |
EPS | -6.22 |
Revenue | 3.92M |
EBITDA | -90.21M |
Income | -93.13M |
Revenue Q/Q | -96.56% |
Revenue Y/Y | -89.64% |
Profit margin | -186.64% |
Oper. margin | -202.75% |
Gross margin | 0% |
EBIT margin | -202.75% |
EBITDA margin | -2301.35% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAffimed N.V. stock price history
Affimed N.V. stock forecast
Affimed N.V. financial statements
| Jun 2023 | 1.39M | -29.39M | -2114.75% |
|---|---|---|---|
| Sep 2023 | 1.96M | -24.35M | -1241.34% |
| Dec 2023 | 413K | -20.20M | -4892.25% |
| Mar 2024 | 155K | -19.17M | -12370.97% |
| Sep 2025 | 535.16K | -11.24M | -2101.34% |
|---|---|---|---|
| Dec 2025 | 6.37M | -243.27M | -3815.16% |
| Dec 2025 | 535.16K | -12.35M | -2308.74% |
| Mar 2026 | 152.96K | -12.38M | -8094.89% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 134711000 | 35.78M | 26.56% |
|---|---|---|---|
| Sep 2023 | 120464000 | 44.04M | 36.56% |
| Dec 2023 | 97157000 | 39.35M | 40.5% |
| Mar 2024 | 70553000 | 29.89M | 42.37% |
| Jun 2023 | -33.33M | -3K | -2.58M |
|---|---|---|---|
| Sep 2023 | -18.25M | -37.45M | -1.61M |
| Dec 2023 | -25.44M | 1.40M | -1.39M |
| Mar 2024 | -23.81M | -1K | -417K |
Affimed N.V. alternative data
| Aug 2023 | 219 |
|---|---|
| Sep 2023 | 219 |
| Oct 2023 | 219 |
| Nov 2023 | 219 |
| Dec 2023 | 219 |
| Jan 2024 | 219 |
| Feb 2024 | 219 |
| Mar 2024 | 219 |
| Apr 2024 | 219 |
| May 2024 | 76 |
| Jun 2024 | 76 |
| Jul 2024 | 76 |
Affimed N.V. other data
48.89%
-17.54%
of AFMD is owned by hedge funds
115
-9
72.03M
-7.35M
shares is hold by hedge funds
| Quarter | Transcript |
|---|---|
| Q1 2024 12 Jun 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 28 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 14 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 10 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Dr. Adi Hoess (1961) Chief Executive Officer, MD & Member of Management Board | $825,050 |
Dr. Wolfgang Fischer (1964) MD, Chief Operating Officer & Member of Management Board | $648,730 |
Dr. Arndt J. G. Schottelius (1966) Chief Scientific Officer | $592,110 |
| Mr. Angus W. Smith (1982) Chief Financial Officer | $529,120 |
Dr. Andreas Harstrick M.D. (1961) Chief Medical Officer | $461,350 |
Affimed: Data Readout Of AFM13 This Quarter Could Push Company Forward
Affimed: Preparing For Key Inflection Points
Affimed Stock: 3 Points For The Bulls
GT Biopharma: Shift In Therapy Strategy Reduces Attractiveness
Affimed: Preparing For A Bullish 2022
Affimed: Remaining Bullish Despite Study Discontinuation
Affimed: Current Fall And Future Prospects
Immutep - Relatively Unknown Pure Play On LAG3 Surrounded By Major Pharma; Positioned Well For Large Biobucks Deal Or Takeout
Affimed: Wholly-Owned Pipeline Programs Support A Long-Term Investment
-
What's the price of Affimed N.V. stock today?
One share of Affimed N.V. stock can currently be purchased for approximately $0.18.
-
When is Affimed N.V.'s next earnings date?
Unfortunately, Affimed N.V.'s (AFMD) next earnings date is currently unknown.
-
Does Affimed N.V. pay dividends?
No, Affimed N.V. does not pay dividends.
-
How much money does Affimed N.V. make?
Affimed N.V. has a market capitalization of 17.79M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 79.99% to 8.28M US dollars.
-
What is Affimed N.V.'s stock symbol?
Affimed N.V. is traded on the NASDAQ under the ticker symbol "AFMD".
-
What is Affimed N.V.'s primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Affimed N.V.?
Shares of Affimed N.V. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Affimed N.V.'s key executives?
Affimed N.V.'s management team includes the following people:
- Dr. Adi Hoess Chief Executive Officer, MD & Member of Management Board(age: 64, pay: $825,050)
- Dr. Wolfgang Fischer MD, Chief Operating Officer & Member of Management Board(age: 61, pay: $648,730)
- Dr. Arndt J. G. Schottelius Chief Scientific Officer(age: 59, pay: $592,110)
- Mr. Angus W. Smith Chief Financial Officer(age: 43, pay: $529,120)
- Dr. Andreas Harstrick M.D. Chief Medical Officer(age: 64, pay: $461,350)
-
How many employees does Affimed N.V. have?
As Jul 2024, Affimed N.V. employs 76 workers, which is 65% less then previous quarter.
-
When Affimed N.V. went public?
Affimed N.V. is publicly traded company for more then 11 years since IPO on 12 Sep 2014.
-
What is Affimed N.V.'s official website?
The official website for Affimed N.V. is affimed.com.
-
How can i contact Affimed N.V.?
Affimed N.V. can be reached via phone at +49 6221 674360.
Affimed N.V. company profile:
Affimed N.V.
affimed.comExchange:
NASDAQ
Full time employees:
76
Industry:
Biotechnology
Sector:
Healthcare
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia; and AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. Affimed N.V. has collaboration agreements with The University of Texas MD Anderson Cancer Center; Genentech, Inc.; and Roivant Sciences Ltd., as well as research funding agreement with The Leukemia & Lymphoma Society. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.
Technologiepark
Heidelberg, 69120
Heidelberg, 69120
CIK: 0001608390
ISIN: NL0015001ZQ0
CUSIP: N01045108
